New Clues in Celiac Disease Epidemiology, Pathogenesis, Clinical Manifestations, and Treatment

REFERENCES

• Fasano A, Catassi C. Current approaches to diagnosis and treatment of celiac disease: an evolving spectrum. Gastroenterology. 2001;120:636–651.
   Google Scholar
• Wolters VM, Wijmenga C. Genetic background of celiac disease and its clinical implications. Am J Gastroenterol. 2008;103:190–195.
   PubMed Web of Science ®Google Scholar
• Romanos J, van Diemen CC, Nolte IM, Analysis of HLA and non-HLA alleles can identify individuals at high risk for celiac disease. Gastroenterology. 2009;137:834–840.
   PubMed Web of Science ®Google Scholar
• Catassi C, Fabiani E, Rätsch IM, The coeliac iceberg in Italy. A multicentre antigliadin antibodies screening for coeliac disease in school-age subjects. Acta Paediatr Suppl. 1996;412:29–35.
   PubMedGoogle Scholar
• Mustalahti K, Catassi C, Reunanen A, The prevalence of CD in Europe: results of a centralized, international mass screening project. Ann Med. 2010;42:587–595.
   PubMed Web of Science ®Google Scholar
• Fasano A, Berti I, Gerarduzzi T, Prevalence of CD in at-risk and non at-risk groups: a large, multicentre study. Arch Intern Med. 2003;163:286–292.
   PubMed Web of Science ®Google Scholar
• Hovell CJ, Collett JA, Vautier G, High prevalence of coeliac disease in a population-based study from Western Australia: a case for screening? Med J Aust. 2001;175:247–250.
   PubMed Web of Science ®Google Scholar
• Cook HB, Burt MJ, Collett JA, Whitehead MR, Frampton CM, Chapman BA. Adult coeliac disease: prevalence and clinical significance. J Gastroenterol Hepatol. 2000;15:1032–1036.
   PubMed Web of Science ®Google Scholar
• Gandolfi L, Pratesi R, Cordoba JC, Tauil PL, Gasparin M, Catassi C. Prevalence of CD among blood donors in Brazil. Am J Gastroenterol. 2000;95:689–692.
   PubMed Web of Science ®Google Scholar
• Oliveira RP, Sdepanian VL, Barreto JA, High prevalence of CD in Brazilian blood donor volunteers based on screening by IgA antitissue transglutaminase antibody. Eur J Gastroenterol Hepatol. 2007;19:43–49.
   PubMed Web of Science ®Google Scholar
• Gomez JC, Selvaggio GS, Viola M, Pizarro B, la Motta G, de Barrio S. Prevalence of CD in Argentina: screening of an adult population in the La Plata area. Am J Gastroenterol. 2001;96:2700–2704.
   PubMed Web of Science ®Google Scholar
• Abu-Zekry M, Kryszak D, Diab M, Catassi C, Fasano A. Prevalence of CD in Egyptian children disputes the east-west agriculture-dependent spread of the disease. J Pediatr Gastroenterol Nutr. 2008;47:136–140.
   PubMed Web of Science ®Google Scholar
• Alarida K, Harown J, Ahmaida A, Coeliac disease in Libyan children: a screening study based on the rapid determination of anti-transglutaminase antibodies. Dig Liver Dis. 2011 (February 8) [Epub ahead of print].
   Google Scholar
• Ben Hariz M, Kallel-Sellami M, Kallel L, Prevalence of CD in Tunisia: mass screening study in schoolchildren. Eur J Gastroenterol Hepatol. 2007;19:687–694.
   PubMed Web of Science ®Google Scholar
• Imanzadeh F, Sayyari AA, Yaghoobi M, Akbari MR, Shafagh H, Farsar AR. CD in children with diarrhea is more frequent than previously suspected. J Pediatr Gastroenterol Nutr. 2005;40:309–311.
   PubMed Web of Science ®Google Scholar
• Ertekin V, Selimoğlu MA, Kardaş F, Aktaş E. Prevalence of CD in Turkish children. J Clin Gastroenterol. 2005;39:689–691.
   PubMed Web of Science ®Google Scholar
• Sood A, Midha V, Sood N, Avasthi G, Sehgal A. Prevalence of CD among school children in Punjab, North India. J Gastroenterol Hepatol. 2006;21:1622–1625.
   PubMed Web of Science ®Google Scholar
• Catassi C, Cobellis G. Coeliac disease epidemiology is alive and kicking, especially in the developing world. Dig Liver Dis. 2007;39:908–910.
   PubMedGoogle Scholar
• Catassi C, Rätsch IM, Gandolfi L, Why is coeliac disease endemic in the people of Sahara? Lancet. 1999;354:647–648.
   PubMed Web of Science ®Google Scholar
• Catassi C, Doloretta Macis M, Rätsch IM, De Virgilis S, Cucca F. The distribution of DQ genes in the Saharawi population provides only a partial explanation for the high CD prevalence. Tissue Antigens. 2001;58:402–406.
   PubMedGoogle Scholar
• Lohi S, Mustalahti K, Kaukinen K, Increasing prevalence of coeliac disease over time. Aliment Pharmacol Ther. 2007;26:1217–1225.
   PubMed Web of Science ®Google Scholar
• Catassi C, Kryszak D, Bhatti B, Natural history of celiac disease autoimmunity in a USA cohort followed since 1974. Ann Med. 2010;42:530–538.
   PubMed Web of Science ®Google Scholar
• Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med. 2002;347:911–920.
   PubMed Web of Science ®Google Scholar
• Ivarsson A, Persson LA, Nyströ ML, Epidemic of coeliac disease in Swedish children. Acta Paediatr. 2000;89:165–171.
   PubMed Web of Science ®Google Scholar
• Gobbetti M, Rizzello GM, Di Cagno R, De Angelis M. Sourdough lactobacilli and celiac disease. Food Microbiol. 2007;24:187–196.
   PubMed Web of Science ®Google Scholar
• Zanoni G, Navone R, Lunari C, In celiac disease, a subset of autoantibodies against transglutaminase binds toll-like receptor 4 and induces activation of monocytes. PLoS Med. 2006;3:e358.
   PubMed Web of Science ®Google Scholar
• Fasano A. Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer. Physiol Rev. 2011;91:151–175.
   PubMed Web of Science ®Google Scholar
• Clemente MG, De Virgiliis S, Kang JS, Early effects of gliadin on enterocyte intracellular signalling involved in intestinal barrier function. Gut. 2003;52:218–223.
   PubMed Web of Science ®Google Scholar
• Drago S, El Asmar R, Di Pierro M, Gliadin, zonulin and gut permeability: effects on celiac and non-celiac intestinal mucosa and intestinal cell lines. Scand J Gastroenterol. 2006;41:408–419.
   PubMed Web of Science ®Google Scholar
• Schumann M, Richter JF, Wedell I, Mechanisms of epithelial translocation of the alpha(2)-gliadin-33mer in coeliac sprue. Gut. 2008;57:747–754.
   PubMed Web of Science ®Google Scholar
• Matysiak-Budnik T, Moura IC, Arcos-Fajardo M, Secretory IgA mediates retrotranscytosis of intact gliadin peptides via the transferrin receptor in CD. J Exp Med. 2008;205:143–154.
   PubMed Web of Science ®Google Scholar
• Tjon JM, van Bergen J, Koning F. CD: How complicated can it get? Immunogenetics. 2010;62: 641–645.
   PubMed Web of Science ®Google Scholar
• Molberg O, McAdam SN, Korner R, Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease. Nat Med. 1998;4:713–717.
   PubMed Web of Science ®Google Scholar
• Vader LW, De RA, van der Wal Y, Specificity of tissue transglutaminase explains cereal toxicity in celiac disease. J Exp Med. 2002;195:643–649.
   PubMed Web of Science ®Google Scholar
• Nilsen EM, Jahnsen FL, Lundin KE, Gluten induces an intestinal cytokine response strongly dominated by interferon gamma in patients with CD. Gastroenterology. 1998;115:551–563.
   PubMed Web of Science ®Google Scholar
• Schuppan D, Junker Y, Barisani D. CD: From pathogenesis to novel therapies. Gastroenterology. 2009;137:1912–1933.
   PubMed Web of Science ®Google Scholar
• Di Sabatino A, Corazza GR. Coeliac disease. Lancet. 2009;373:1480–1493.
   PubMed Web of Science ®Google Scholar
• Meresse B, Curran SA, Ciszewski C, Reprogramming of CTLs into natural killer-like cells in CD. J Exp Med. 2006;203:1343–1355.
   PubMed Web of Science ®Google Scholar
• Meresse B, Chen Z, Ciszewski C, Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in CD. Immunity. 2004;21:357–366.
   PubMed Web of Science ®Google Scholar
• Jabri B, Sollid LM. Tissue-mediated control of immunopathology in coeliac disease. Nat Rev Immunol. 2009;9:858–870.
   PubMed Web of Science ®Google Scholar
• Maiuri L, Ciacci C, Ricciardelli I, Association between innate response to gliadin and activation of pathogenic T cells in coeliac disease. Lancet. 2003;362:30–37.
   PubMed Web of Science ®Google Scholar
• Londei M, Ciacci C, Ricciardelli I, Gliadin as a stimulator of innate responses in celiac disease. Mol Immunol. 2005;42:913–918.
   PubMed Web of Science ®Google Scholar
• Wierink CD, van Diermen DE, Aartman IH, Heymans HS. Dental enamel defects in children with coeliac disease. Int J Paediatr Dent. 2007;17:163–168.
   PubMed Web of Science ®Google Scholar
• Bucci P, Carile F, Sangianantoni A, D'Angiò F, Santarelli A, Lo Muzio L. Oral aphthous ulcers and dental enamel defects in children with coeliac disease. Acta Paediatr. 2006;95:203–207.
   PubMed Web of Science ®Google Scholar
• Rubio-Tapia A, Murray JA. The liver in celiac disease. Hepatology. 2007;46:1650–1658.
   PubMed Web of Science ®Google Scholar
• Halfdanarson TR, Litzow MR, Murray JA. Hematologic manifestations of celiac disease. Blood. 2007;109:412–421.
   PubMed Web of Science ®Google Scholar
• Hershko C, Patz J. Ironing out the mechanism of anemia in celiac disease. Haematologica. 2008;93:1761–1765.
   PubMed Web of Science ®Google Scholar
• Nicolas ME, Krause PK, Gibson LE, Murray JA. Dermatitis herpetiformis. Int J Dermatol. 2003;42: 588–600.
   PubMed Web of Science ®Google Scholar
• van Rijn JC, Grote FK, Oostdijk W, Wit JM. Short stature and the probability of coeliac disease, in the absence of gastrointestinal symptoms. Arch Dis Child. 2004;89:882–883.
   PubMed Web of Science ®Google Scholar
• Fasano A, Counts D. Commentary on “anti-pituitary antibodies in children with newly diagnosed celiac disease: a novel finding contributing to linear growth”. Am J Gastroenterol. 2010;105:697–698.
   PubMed Web of Science ®Google Scholar
• Delvecchio M, De Bellis A, Francavilla R, Anti-pituitary antibodies in children with newly diagnosed celiac disease: a novel finding contributing to linear-growth impairment. Am J Gastroenterol. 2010;105:691–696.
   PubMed Web of Science ®Google Scholar
• Gadewar S, Fasano A. Celiac disease: is the atypical really typical? Summary of the recent National Institutes of Health Consensus Conference and latest advances. Curr Gastroenterol Rep. 2005;7:455–461.
   Google Scholar
• Mora S. Celiac disease in children: impact on bone health. Rev Endocr Metab Disord. 2008;9:123–130.
   PubMed Web of Science ®Google Scholar
• Stenson WF, Newberry R, Lorenz R, Baldus C, Civitelli R. Increased prevalence of celiac disease and need for routine screening among patients with osteoporosis. Arch Intern Med. 2005;165:393–399.
   PubMedGoogle Scholar
• Fasano A, Catassi C. Coeliac disease in children. Best Pract Res Clin Gastroenterol. 2005;19:467–468.
   PubMed Web of Science ®Google Scholar
• Bushara KO. Neurologic presentation of CD. Gastroenterology. 2005;128:S92–S97.
   PubMed Web of Science ®Google Scholar
• Lionetti E, Francavilla R, Pavone P, The neurology of coeliac disease in childhood: what is the evidence? A systematic review and meta-analysis. Dev Med Child Neurol. 2010;52:700–707.
   PubMed Web of Science ®Google Scholar
• Holmes GKT. Screening for coeliac disease in type 1 diabetes. Arch Dis Child. 2002; 87:495–499.
   PubMed Web of Science ®Google Scholar
• Larizza D, Calcaterra V, De Giacomo C, Coeliac disease in children with autoimmune thyroid disease. J Pediatr. 2001;139:738–740.
   PubMed Web of Science ®Google Scholar
• Book L, Hart A, Black J, Prevalence and clinical characteristics of CD in Down's syndrome in a U.S. study. Am J Med Gen. 2001;98:70–74.
   PubMed Web of Science ®Google Scholar
• Haboubi NY, Taylor S, Jones S. Coeliac disease and oats: a systematic review. Postgrad Med J. 2006;82:672–678.
   PubMed Web of Science ®Google Scholar
• Hopman EG, Le Cessie S, von Blomberg BM, Mearin ML. Nutritional management of the gluten-free diet in young people with CD in the Netherlands. J Pediatr Gastroenterol Nutr. 2006;43:102–108.
   PubMed Web of Science ®Google Scholar
• Catassi C, Fabiani E, Iacono G, A prospective, double-blind, placebo-controlled trial to establish a safe gluten threshold for patients with celiac disease. Am J Clin Nutr. 2007;85:160–166.
   PubMed Web of Science ®Google Scholar
• Tack GJ, Verbeek WH, Schreurs MW, Mulder CJ. The spectrum of celiac disease: epidemiology, clinical aspects and treatment. Nat Rev Gastroenterol Hepatol. 2010;7:204–213.
   PubMed Web of Science ®Google Scholar
• Schuppan D, Junker Y, Barisani D. Celiac disease: from pathogenesis to novel therapies. Gastroenterology. 2009;137:1912–1933.
   PubMed Web of Science ®Google Scholar
• Lerner A. New therapeutic strategies for celiac disease. Autoimmun Rev. 2010;9:144–147.
   PubMed Web of Science ®Google Scholar
• Frisoni M, Corazza GR, Lafiandra D, Wheat deficient in gliadins: Promising tool for treatment of coeliac disease. Gut. 1995;36:375–378.
   PubMed Web of Science ®Google Scholar
• Spaenij-Dekking L, Kooy-Winkelaar Y, van Veelen P, Natural variation in toxicity of wheat: potential for selection of nontoxic varieties for celiac disease patients. Gastroenterology. 2005;129:797–806.
   PubMed Web of Science ®Google Scholar
• Pizzuti D, Buda A, D'Odorico A, Lack of intestinal mucosal toxicity of Triticum monococcum in celiac disease patients. Scand J Gastroenterol. 2006;41:1305–1311.
   PubMed Web of Science ®Google Scholar
• Gianfrani C, Siciliano RA, Facchiano AM, Transamidation of wheat flour inhibits the response to gliadin of intestinal T cells in celiac disease. Gastroenterology. 2007;133:780–789.
   PubMed Web of Science ®Google Scholar
• Di Cagno R, De Angelis M, Auricchio S, Sourdough bread made from wheat and nontoxic flours and started with selected lactobacilli is tolerated in celiac sprue patients. Appl Environ Microbiol. 2004;70:1088–1096.
   PubMed Web of Science ®Google Scholar
• Stepniak D, Spaenij-Dekking L, Mitea C, Highly efficient gluten degradation with a newly identified prolyl endoprotease: implications for celiac disease. Am J Physiol Gastrointest Liver Physiol. 2006;291:621–629.
   PubMed Web of Science ®Google Scholar
• Mitea C, Havenaar R, Drijfhout JW, Efficient degradation of gluten by a prolyl endoprotease in a gastrointestinal model: implications for coeliac disease. Gut. 2008;57:25–32.
   PubMed Web of Science ®Google Scholar
• Gass J, Bethune MT, Siegel M, Combination enzyme therapy for gastric digestion of dietary gluten in patients with celiac sprue. Gastroenterology. 2007;133:472–480.
   PubMed Web of Science ®Google Scholar
• Pinier M, Verdu EF, Nasser-Eddine M, Polymeric binders suppress gliadin-induced toxicity in the intestinal epithelium. Gastroenterology. 2009;136:288–298.
   PubMed Web of Science ®Google Scholar
• Kelly CP, Green PH, Murray JA, Intestinal permeability of larazotide acetate in celiac disease: results of a phase IIB 6-week gluten-challenge clinical trial [abstract]. Gastroenterology. 2009;136(Suppl 1):A474.
   Google Scholar
• Molberg O, McAdam S, Lundin KE, T cells from celiac disease lesions recognize gliadin epitopes deamidated in situ by endogenous tissue transglutaminase. Eur J Immunol. 2001;31:1317–1323.
   PubMed Web of Science ®Google Scholar
• Maiuri L, Ciacci C, Ricciardelli I, Unexpected role of surface transglutaminase type II in celiac disease. Gastroenterology. 2005;129:1400–1413.
   PubMed Web of Science ®Google Scholar
• Kapoerchan VV, Wiesner M, Overhand M, Design of azidoproline containing gluten peptides to suppress CD4+ T-cell responses associated with celiac disease. Bioorg Med Chem. 2008;16:2053–2062.
   PubMed Web of Science ®Google Scholar
• Xia J, Siegel M, Bergseng E, Inhibition of HLA-DQ2-mediated antigen presentation by analogues of a high affinity 33-residue peptide from alpha2-gliadin. J Am Chem Soc. 2006;128:1859–1867.
   PubMed Web of Science ®Google Scholar
• Siegel M, Xia J, Khosla C. Structure-based design of alphaamido aldehyde containing gluten peptide analogues as modulators of HLA-DQ2 and transglutaminase 2. Bioorg Med Chem. 2007;15: 6253–6261.
   PubMed Web of Science ®Google Scholar
• Xia J, Bergseng E, Fleckenstein B, Cyclic and dimeric gluten peptide analogues inhibiting DQ2-mediated antigen presentation in celiac disease. Bioorg Med Chem. 2007;15:6565–6573.
   PubMed Web of Science ®Google Scholar
• Keech CL, Dromey J, Chen Z, Immune tolerance induced by peptide immunotherapy in an HLA-DQ2-dependent mouse model of gluten immunity. Gastroenterology. 2009;136:A355.
   Web of Science ®Google Scholar
• Baslund B, Tvede N, Danneskiold-Samsoe B, Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study. Arthritis Rheum. 2005;52:2686–2692.
   PubMed Web of Science ®Google Scholar
• Hommes DW, Mikhajlova TL, Stoinov S, Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease. Gut. 2006;55(8):1131–1137.
   PubMed Web of Science ®Google Scholar
• Costantino G, della Torre A, Lo Presti MA, Treatment of life-threatening type I refractory coeliac disease with long-term infliximab. Dig Liver Dis. 2008;40:74–77.
   PubMedGoogle Scholar
• Vivas S, Ruiz de Morales JM, Ramos F, Alemtuzumab for refractory celiac disease in a patient at risk for enteropathy-associated T-cell lymphoma. N Engl J Med. 2006;354:2514–2515.
   PubMed Web of Science ®Google Scholar
• Salvati VM, Mazzarella G, Gianfrani C, Recombinant human interleukin 10 suppresses gliadin dependent T cell activation in ex vivo cultured coeliac intestinal mucosa. Gut. 2005;54:46–53.
   PubMed Web of Science ®Google Scholar
• Silano M, Agostoni C, Guandalini S. Effect of the timing of gluten introduction on the development of celiac disease. World J Gastroenterol. 2010;16:1939–1942.
   PubMed Web of Science ®Google Scholar